Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicines Company gains anti-infectives in $140m Rempex buy

This article was originally published in Scrip

Executive Summary

The Medicines Company (MDCO) added a Phase III-ready drug candidate and other anti-infective programs to its pipeline via the acquisition of privately-held, San Diego-based Rempex Pharmaceuticals for $140m up front and up to $334m in milestone payments.

You may also be interested in...



Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch

Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.

Phase III Data Give Medicines Company's Carbavance A Chance To Best Antibiotic Competitors

The Medicines Co. is a few years behind its most recent beta-lactamase inhibitor competitors, but its antibiotic Carbavance is the only one with pivotal data that show superiority to a well-known drug in the same class for the treatment of hospital-based urinary tract infections.

BMS Makes The Case For A Lasting Hematology Legacy

Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.

Related Companies

UsernamePublicRestriction

Register

SC023681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel